Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo Nordisk AS (NVO) reports a strong 26% increase in sales and operating profit, with significant growth in obesity care ...
Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.
Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...
Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
LONDON (Reuters) – The Novo Nordisk Foundation does not plan to step in to prop ... Rob Nabors, who leads the Gates ...
Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...